8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
- --------------------------------------------------------------------------------

                                    FORM 8-K



                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

                       THE SECURITIES EXCHANGE ACT OF 1934



       Date of Report (Date of Earliest Event Reported): November 13, 2001



                         Commission file number 1-12215


                         Quest Diagnostics Incorporated
                               One Malcolm Avenue
                               Teterboro, NJ 07608
                                  (201)393-5000


                                    Delaware
                            (State of Incorporation)


                                   16-1387862
                     (I.R.S. Employer Identification Number)






Item 9. Regulation FD Disclosure.

Kenneth W. Freeman, Chairman and Chief Executive Officer of Quest Diagnostics
Incorporated (the "Company"), is scheduled to speak at the Credit Suisse First
Boston Thirteenth Annual Health Care Conference on November 14, 2001 at the
Arizona Biltmore Resort and Spa in Phoenix, Arizona. To comply with the
Securities and Exchange Commission's Regulation FD, the Company is filing this
report to update all investors on its outlook.

Mr. Freeman will report the following: "Our outlook remains unchanged from the
guidance we provided during our Third Quarter 2001 financial conference call on
October 19, 2001. We remain comfortable with the consensus of analyst
expectations for fourth quarter earnings of $0.48 per diluted share, as reported
by First Call. We continue to expect full year earnings per diluted share before
special items to grow more than 65%. In 2002, we continue to expect to deliver
earnings per share growth in excess of 30%. This increase is before the
additional $0.35 per diluted share we expect to realize from the change in
goodwill accounting that becomes effective on January 1, 2002. We continue to
remain highly confident in our ability to deliver sustainable outstanding
performance for our shareholders."

The statements in this report which are not historical facts or information may
be forward-looking statements. These forward-looking statements involve risks
and uncertainties that could cause the outcome to be materially different.
Certain of these risks and uncertainties are listed in the Quest Diagnostics
Incorporated 2000 Form 10-K and subsequent filings.

Exhibit No.

99.1            Press Release regarding certain comments by registrant on
                November 14, 2001



                                    Signature


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                            November 14, 2001

                                            QUEST DIAGNOSTICS INCORPORATED



                                            By:  /s/  Robert A. Hagemann
                                               ---------------------------------
                                                 Robert A. Hagemann
                                                 Corporate Vice President and
                                                 Chief Financial Officer



                                                                               2

EX-99.1

                                                                    Exhibit 99.1




                          QUEST DIAGNOSTICS TO SPEAK AT
                CREDIT SUISSE FIRST BOSTON HEALTH CARE CONFERENCE

TETERBORO, N.J., NOVEMBER 13, 2001--Quest Diagnostics Incorporated (NYSE: DGX),
the nation's leading provider of diagnostic testing, information and services,
announced that Kenneth W. Freeman, Chairman and Chief Executive Officer, is
scheduled to speak at the Credit Suisse First Boston Thirteenth Annual Health
Care Conference tomorrow at the Arizona Biltmore Resort and Spa in Phoenix. The
conference is not being webcast, and to comply with the Securities and Exchange
Commission's Regulation FD, the company is issuing the following statement to
update all investors on its outlook.

"Our outlook remains unchanged from the guidance we provided during our Third
Quarter 2001 financial conference call on October 19, 2001," said Mr. Freeman.
"We remain comfortable with the consensus of analyst expectations for fourth
quarter earnings of $0.48 per diluted share, as reported by First Call. We
continue to expect full year earnings per diluted share before special items to
grow more than 65%. In 2002, we continue to expect to deliver earnings per share
growth in excess of 30%. This increase is before the additional $0.35 per
diluted share we expect to realize from the change in goodwill accounting that
becomes effective on January 1, 2002. We continue to remain highly confident in
our ability to deliver sustainable outstanding performance for our
shareholders."

Quest Diagnostics is the nation's leading provider of diagnostic testing,
information and services with $3.4 billion in annual revenues. The company's
diagnostic testing yields information that enables health care professionals and
consumers to make better decisions to improve health. Quest Diagnostics offers
patients and physicians the broadest access to diagnostic testing services
through its national network of approximately 30 full-service laboratories, 150
rapid response laboratories and more than 1,300 patient service centers, where
specimens are collected. Quest Diagnostics is the leading provider of esoteric
testing, including gene-based testing, and is the leader in routine medical
testing, drugs of abuse testing, and non-hospital-based anatomic pathology
testing. Quest Diagnostics empowers health care organizations and clinicians
with state-of-the-art connectivity solutions that improve practice management.
Through partnerships with pharmaceutical, biotechnology and information
technology companies, Quest Diagnostics provides support to help speed the
development of health care insights and new therapeutics. Additional company
information can be found on the Internet at: www.questdiagnostics.com.

The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause the outcome to be materially
different. Certain of these risks and uncertainties are listed in the Quest
Diagnostics Incorporated 2000 Form 10-K and subsequent filings.

                                      # # #


                                                                               3